GlassScriptPhysician profile
Samuel C Kim
NPI 1134129679
$3,322.93
in general payments reported to CMS, 2019-2025
34 companies · $90.66 in 2025
The $90.66 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $591 · 2021: $966 · 2022: $680 · 2023: $18.95 · 2024: $105 · 2025: $90.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $686.67 | 2019-2022 | |
| Janssen Biotech, INC. | $311.28 | 2019-2022 | |
| Boston Scientific Corporation | $308.45 | 2019-2025 | General - Bph, Spaceoar Vue System - 10ml |
| Coloplast Corp | $247.82 | 2019-2022 | |
| Abbvie INC. | $158.01 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $154.42 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.51 | 2019-2022 | |
| Pfizer INC. | $148.78 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $129.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.06 | 2019 | |
| Axonics, INC. | $116.26 | 2020-2024 | Axonics, Bulkamid |
| Ethicon US, LLC | $109.60 | 2021 | |
| Myovant Sciences INC. | $94.43 | 2021-2022 | |
| Blue Earth Diagnostics | $73.15 | 2021-2022 | |
| Antares Pharma, INC. | $63.94 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $57.63 | 2020-2021 | |
| Clarus Therapeutics INC. | $47.48 | 2021 | |
| Sun Pharmaceutical Industries INC. | $41.97 | 2022 | |
| Urovant Sciences INC | $33.11 | 2021-2022 | |
| Procept Biorobotics Corporation | $30.19 | 2021 | |
| Genzyme Corporation | $23.61 | 2021 | |
| Amgen INC. | $22.18 | 2019 | |
| Neotract INC. | $20.80 | 2020 | |
| Medline Industries LP | $20.08 | 2022 | |
| Davol INC. | $18.28 | 2021 | |
| Progenics Pharmaceuticals, INC. | $17.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.56 | 2022 | |
| Acerus Pharmaceuticals Corporation | $17.45 | 2022 | |
| Accord Healthcare, INC. | $13.88 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $13.55 | 2019 | |
| Convatec INC. | $13.47 | 2021 | |
| Urogen Pharma, INC. | $13.20 | 2022 | |
| Duchesnay USA Incorporated | $12.67 | 2019 | |
| Allergan, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.